Shopping Cart
- Remove All
Your shopping cart is currently empty
Indirubin Derivative E804
🥰Excellent
Catalog No. T11654Cas No. 854171-35-0
Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity.
Indirubin Derivative E804
🥰Excellent
Purity: 98.75%
Catalog No. T11654Cas No. 854171-35-0
Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $42 | In Stock | |
| 5 mg | $92 | In Stock | |
| 10 mg | $133 | In Stock | |
| 25 mg | $218 | In Stock | |
| 50 mg | $325 | In Stock | |
| 100 mg | $483 | In Stock | |
| 200 mg | $691 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Indirubin Derivative E804"
Brigatinib
Cited
AP-26113
T36211197953-54-0
Brigatinib (AP-26113) is a highly potent and selective inhibitor of ALK.
- $30
Size
QTY
CitedInsulin (human)
Cited
Insulin(human), INSULIN
T822111061-68-0
Insulin (human) is a peptide hormone that promotes glycogen synthesis and regulates glucose levels in the blood. Insulin (human) has hypoglycemic activity and is used clinically to treat hyperglycemia in diabetic patients.
- $30
Size
QTY
CitedTyrphostin AG 538
AG 538
T67707133550-18-2In house
Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (ICâ‚…0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.
- $100
Size
QTY
Picropodophyllin Cited
PPP, Picropodophyllotoxin, AXL1717
T6943477-47-4
Picropodophyllin (Picropodophyllin (PPP)) (PPP) is a specific IGF-1R inhibitor (IC50: 1 nM). Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT).
- $58
Size
QTY
CitedCeritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedGSK1904529A Cited
GSK 4529
T60031089283-49-7In house
GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
- $34
Size
QTY
CitedI-OMe-Tyrphostin AG 538
I-OMe-AG 538
T115931094048-77-7In house
I-OMe-Tyrphostin AG 538 is a specific IGF-1R inhibitor and ATP-competitive inhibitor of PI5P4Kα (IC50: 1 µM).I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and exhibits preferential cytotoxicity to nutrient-deficient PANC1 cells.
- $51
Size
QTY
ALK-IN-1
Brigatinib-analog, AP26113-analog, AP26113
T30591197958-12-5
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
- $40
Size
QTY
Urolithin C Cited
TN7108165393-06-6
Urolithin C is a gut metabolite of ellagic acid. Urolithin C induces apoptosis in PC12 cells through a mitochondria-mediated pathway.
- $48
Size
QTY
CitedPD173074 Cited
T2642219580-11-7
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
- $36
Size
QTY
CitedLinsitinib Cited
OSI-906
T6017867160-71-2
OSI-906 (Linsitinib (OSI-906)) is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.
- $33
Size
QTY
CitedHNMPA
T21761132541-52-7In house
HNMPA is a membrane impermeable inhibitor of insulin receptor tyrosine kinase. HNMPA inhibits tyrosine and serine autophosphorylation by the human insulin receptor. HNMPA exhibits no effect on cyclic AMP-dependent protein kinase or protein kinase C activities.
- $43
Size
QTY
Select Batch
Purity:98.75%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity. |
| Targets&IC50 | CDK2-CyclinE:0.23 μM (EC50), IGF-1R:0.65 μM |
| In vitro | Indirubin Derivative E804 is a water-soluble derivative that effectively inhibits insulin-like growth factor 1 receptor (IGF1R) with an IC50 of 0.65 μM. In addition, Indirubin Derivative E804 also inhibits CDK2/CycE with an EC50 of 0.23 μM. [1] |
| Molecular Weight | 365.38 |
| Formula | C20H19N3O4 |
| Cas No. | 854171-35-0 |
| Smiles | O=C1NC=2C=CC=CC2C1=C3NC=4C=CC=CC4C3=NOCCC(O)CO |
| Relative Density. | 1.44 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (273.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Indirubin Derivative E804 | purchase Indirubin Derivative E804 | Indirubin Derivative E804 cost | order Indirubin Derivative E804 | Indirubin Derivative E804 chemical structure | Indirubin Derivative E804 in vitro | Indirubin Derivative E804 formula | Indirubin Derivative E804 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.